New breast cancer drug under Real-World scrutiny
NCT ID NCT07358182
Summary
This study is observing 300 patients with HER2-positive or HER2-low breast cancer who are already receiving or scheduled to receive trastuzumab-rezetecan treatment in real-world clinical settings. The goal is to collect information about how well the treatment works and what side effects patients experience during their regular care. Researchers will track tumor responses, survival outcomes, and safety data without changing patients' treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.